Martin A Walter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/711695/publications.pdf

Version: 2024-02-01

90 papers	7,530 citations	66343 42 h-index	53230 85 g-index
95 all docs	95 docs citations	95 times ranked	8633 citing authors

#	Article	IF	Citations
1	Somatostatin Receptorâ€“Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. Journal of Nuclear Medicine, 2021, 62, 507-513.	5.0	37
2	Intra-vagal parathyroid adenoma on digital PET/CT with 18F-fluorocholine. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4521-4522.	6.4	0
3	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013700.	2.8	7
4	Variations in radioiodine ablation: decision-making after total thyroidectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 554-560.	6.4	7
5	Radioisotope imaging for discriminating benign from malignant cytologically indeterminate thyroid nodules. Gland Surgery, 2019, 8, S118-S125.	1.1	14
6	Association of Surgical Volume and Quality Management in Thyroid Surgery: A Twoâ€Nation Multicenter Study. World Journal of Surgery, 2019, 43, 2218-2227.	1.6	6
7	Therapeutic Options for Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 480.	7.1	67
8	The Role of Positron Emission Tomographyâ€“Computed Tomography in the Workup of Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e1915873.	5.9	2
9	MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer. Journal of Nuclear Medicine, 2019, 60, 917-923.	5.0	7
10	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocrine-Related Cancer, 2019, 26, 227-239.	3.1	114
11	FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1250-1269.	6.4	332
12	Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 159-168.	1.0	6
13	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. Journal of Pediatrics, 2017, 184, 209-214.e1.	1.8	23
14	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149
15	Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues. Journal of Nuclear Medicine, 2017, 58, 1532.1-1532.	5.0	0
16	Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2017, 20, 909-918.	2.1	43
17	The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 468-475.	6.4	52
18	Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 97-102.	5.0	7

#	Article	IF	Citations
19	Reply: Somatostatin Receptorâ€“Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma. Journal of Nuclear Medicine, 2016, 57, 1657.2-1658.	5.0	0
20	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. PLoS Medicine, 2016, 13, e1002046.	8.4	20
21	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. Critical Care Medicine, 2016, 44, 130-137.	0.9	28
22	Upregulation of Key Molecules for Targeted Imaging and Therapy. Journal of Nuclear Medicine, 2016, 57, 1805-1810.	5.0	54
23	2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 2016, 26, 1343-1421.	4.5	1,757
24	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. Journal of Clinical Epidemiology, 2016, 69, 152-160.	5.0	19
25	¹⁸ F-RB390: Innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate, 2015, 75, 348-359.	2.3	3
26	Completion and Publication Rates of Randomized Controlled Trials in Surgery. Annals of Surgery, 2015, 262, 68-73.	4.2	45
27	Somatostatin Receptorâ€“Targeted Radiopeptide Therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial. Journal of Nuclear Medicine, 2015, 56, 171-176.	5.0	63
28	Towards tailored radiopeptide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1231-1237.	6.4	12
29	Planning and reporting of quality-of-life outcomes in cancer trials. Annals of Oncology, 2015, 26, 1966-1973.	1.2	47
30	Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 46-55.	1.0	15
31	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, The, 2014, 349, g4539-g4539.	6.0	74
32	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. JAMA - Journal of the American Medical Association, 2014, 311, 1045.	7.4	265
33	Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 214-222.	6.4	69
34	On transcending the impasse of respiratory motion correction applications in routine clinical imaging - a consideration of a fully automated data driven motion control framework. EJNMMI Physics, 2014, 1, 8.	2.7	68
35	Indium-111 labeled gold nanoparticles for in-vivo molecular targeting. Biomaterials, 2014, 35, 7050-7057.	11.4	41
36	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, The, 2014, 349, g4921-g4921.	6.0	5

#	Article	IF	Citations
37	Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. Journal of Translational Medicine, 2013, 11, 17.	4.4	24
38	Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design. Trials, 2013, 14, 335.	1.6	4
39	1,2,3â€Triazoles as Amide Bond Mimics: Triazole Scan Yields Proteaseâ€Resistant Peptidomimetics for Tumor Targeting. Angewandte Chemie - International Edition, 2013, 52, 8957-8960.	13.8	153
40	Impact of 3,4-Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective. Journal of Nuclear Medicine, 2012, 53, 393-398.	5.0	49
41	Treatment of Progressive Dedifferentiated and Medullary Thyroid Cancer with Radiolabeled Somatostatin Analogs. Medical Radiology, 2012, , 323-332.	0.1	0
42	Cohort Study of Somatostatin-Based Radiopeptide Therapy With [⁹⁰Y-DOTA]-TOC Versus [⁹⁰Y-DOTA]-TOC Plus [¹⁷⁷Lu-DOTA]-TOC in Neuroendocrine Cancers. Journal of Clinical Oncology, 2012, 30, 1100-1106.	1.6	182
43	The Influence of Different Metal-Chelators on the Biological Profile of Nanoparticles for Gallium-68 Based Molecular Imaging. Journal of Nano Research, 2012, 20, 21-31.	0.8	1
44	Is There a Need for Dedicated Bone Imaging in Addition to 18F-FDG PET/CT Imaging in Pediatric Sarcoma Patients?. Journal of Pediatric Hematology/Oncology, 2012, 34, 131-136.	0.6	33
45	Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Medical Research Methodology, 2012, 12, 131.	3.1	33
46	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
47	Radioactive Therapy and External Radiotherapy of Thyroid Cancer. , 2012, , 313-326.		0
48	¹⁸F-FluoroDeoxyGlucose Uptake of Bone and Soft Tissue Sarcomas in Pediatric Patients. Pediatric Hematology and Oncology, 2011, 28, 579-587.	0.8	13
49	99mTc-DPD-SPECT/CT predicts the outcome of imaging-guided diagnostic anaesthetic injections: A prospective cohort study. European Journal of Radiology, 2011, 80, e410-e415.	2.6	41
50	Research update for articles published in EJCI in 2009. European Journal of Clinical Investigation, 2011, 41, 1149-1163.	3.4	0
51	Peptide receptor radioligand therapy is an effective treatment for the longâ€term stabilization of malignant gastrinomas. Cancer, 2011, 117, 1377-1385.	4.1	43
52	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation, 2011, 32, 51-58.	2.5	117
53	Metabolic Imaging Allows Early Prediction of Response to Vandetanib. Journal of Nuclear Medicine, 2011, 52, 231-240.	5.0	13
54	Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [⁹⁰Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. Journal of Clinical Oncology, 2011, 29, 2416-2423.	1.6	571

#	Article	IF	Citations
55	Procalcitonin levels predict clinical course and progressionâ€free survival in patients with medullary thyroid cancer. Cancer, 2010, 116, 31-40.	4.1	49
56	Correlation of 6-¹⁸F-Fluoro-l-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas. Journal of Nuclear Medicine, 2010, 51, 1532-1538.	5.0	141
57	Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53â^'/â^' Mice. Journal of Nuclear Medicine, 2010, 51, 1285-1292.	5.0	11
58	¹⁸F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas. Journal of Nuclear Medicine, 2009, 50, 513-519.	5.0	90
59	Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1938-1944.	3.6	112
60	Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2847-2852.	7.1	54
61	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research, 2009, 69, 3650-3656.	0.9	178
62	[⁹⁰YttriumâEDOTA]â€TOC response is associated with survival benefit in iodineâ€refractory thyroid cancer. Cancer, 2009, 115, 2052-2062.	4.1	46
63	Different strategies to overcome the effect of carbimazole on highâ€and lowâ€dose radioiodine therapy: results from continuous doseâ€"effect models. European Journal of Clinical Investigation, 2009, 39, 51-57.	3.4	11
64	Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1868-1877.	6.4	87
65	Distinguishing specific sexual and general emotional effects in fMRIâ€"Subcortical and cortical arousal during erotic picture viewing. NeuroImage, 2008, 40, 1482-1494.	4.2	191
66	Graves' Disease. New England Journal of Medicine, 2008, 359, 1407-1409.	27.0	7
67	Impact of Screening Kindreds for SDHD p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4818-4825.	3.6	28
68	The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study. Journal of Nuclear Medicine, 2007, 48, 1620-1625.	5.0	60
69	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
70	Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2007, 334, 514.	2.3	155
71	Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial. Clinical Cancer Research, 2007, 13, 6696-6702.	7.0	156
72	Reply: 18F-FDG PET in Planning Radiation Treatment of Non Small Cell Lung Cancer: Where Exactly Is the Tumor?. Journal of Nuclear Medicine, 2007, 48, 1403-1403.	5.0	1

#	Article	IF	Citations
73	Antithyroid Drugs and Radioiodine and the Absence of Evidence. Journal of Nuclear Medicine, 2007, 48, 1403a-1403a.	5.0	0
74	Influence of Different Spacers on the Biological Profile of a DOTAâ˜Somatostatin Analogue. Bioconjugate Chemistry, 2007, 18, 84-92.	3.6	67
75	[18F]Fluorodeoxyglucose PET in Large Vessel Vasculitis. Radiologic Clinics of North America, 2007, 45, 735-744.	1.8	67
76	[18F]Fluorodeoxyglucose PET in Large Vessel Vasculitis. PET Clinics, 2006, 1, 179-189.	3.0	1
77	Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues. Pathology, 2006, 38, 249-253.	0.6	9
78	Outcome of radioiodine therapy without, on or 3Âdays off carbimazole: a prospective interventional three-group comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 730-737.	6.4	47
79	Coregistered Iodine-131 Single Photon Emission Computed Tomograpy/Computed Tomography Reveals Dedifferentiation in a Metastatic Follicular Thyroid Carcinoma. Thyroid, 2006, 16, 1063-1064.	4.5	5
80	The detrimental effect of anti-thyroid drugs on the outcome of radioiodine therapy is not directly due to decreased radioiodine uptake. Nuclear Medicine Communications, 2005, 26, 70.	1.1	1
81	The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 674-681.	6.4	334
82	[18F]FDG-PET of giant-cell aortitis. Rheumatology, 2005, 44, 690-691.	1.9	19
83	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <EMPH TYPE="ITAL">SDHC</EMPH> Gene. JAMA - Journal of the American Medical Association, 2005, 294, 2057.	7.4	309
84	Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clinical Cancer Research, 2005, 11, 1136-45.	7.0	73
85	Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. Journal of Nuclear Medicine, 2005, 46, 1561-9.	5.0	66
86	Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison. Nuklearmedizin - NuclearMedicine, 2005, 44, 33-6.	0.7	11
87	Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. European Journal of Clinical Investigation, 2004, 34, 365-370.	3.4	44
88	Enhancement of radioiodine uptake in hyperthyroidism by administration of hydrochlorothiazide. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 474-474.	6.4	0
89	Situs inversus completus. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1202-1202.	6.4	1
90	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 0, , .	2.8	1